<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In practice, cases of therapy-related <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) are often classified according to morphologic schemes used for de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>However, there are few data addressing the appropriateness of such classification </plain></SENT>
<SENT sid="2" pm="."><plain>We studied 155 patients with therapy-related <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>)/t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> to determine whether subclassification by the World Health Organization (WHO) criteria for de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> provides prognostic information in t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>In addition, we assessed whether cytogenetic stratification by the International Prognostic Scoring System (IPSS) guidelines or karyotypic complexity was prognostically important </plain></SENT>
<SENT sid="4" pm="."><plain>We found no differences in median survival times among patients classified into the different WHO subgroup of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or according to their bone marrow blast percentage; our results indicate a uniformly poor outcome in t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> regardless of morphologic classification </plain></SENT>
<SENT sid="5" pm="."><plain>However, significant survival differences correlated with cytogenetic stratification according to IPSS guidelines and/or karyotypic complexity </plain></SENT>
<SENT sid="6" pm="."><plain>We found only a borderline difference in median survival of patients with an initial t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> diagnosis compared with patients with an initial t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> diagnosis </plain></SENT>
</text></document>